Primary drug resistance is certainly linked to the genetic lesions driving AML; for example, leukemias with an NPM1mut FLT3-ITD genotype are substantially more difficult to cure with chemotherapy alone than NPM1mut AMLs that lack FLT3-ITD, although the reasons for such differential sensitivity remain obscure. The gene discussed is FLT3; the disease is leukemia.